Soligenix Plans To Initiate Patient Enrollment In The Confirmatory FLASH 2 Study With HyBryte By The End Of 2024; Continues To Explore The Potential Of HyBryte In Treating Other Dermatological Conditions Such As Psoriasis
Portfolio Pulse from Benzinga Newsdesk
Soligenix, Inc. (NASDAQ:SNGX) plans to initiate patient enrollment in the confirmatory FLASH 2 study with HyBryte™ by the end of 2024. The company is also exploring the potential of HyBryte™ in treating other dermatological conditions such as psoriasis, with a Phase 2 study ongoing.
August 01, 2024 | 1:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Soligenix is advancing its investigational drug HyBryte™ for Cutaneous T-Cell Lymphoma (CTCL) with plans to start patient enrollment in the FLASH 2 study by the end of 2024. The company is also exploring HyBryte™ for other dermatological conditions like psoriasis, with a Phase 2 study ongoing.
The initiation of patient enrollment in the FLASH 2 study and ongoing exploration of HyBryte™ for other conditions like psoriasis are positive developments. These steps indicate progress in their pipeline, which could boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100